OR WAIT null SECS
announced it has completed the acquisition of Kendle International Inc. in an all-cash transaction with a total equity value of approximately $232 million or $15.25 per share. The combined company will operate as INC Research, LLC and will be led by James T. Ogle, Chief Executive Officer. Serving in key corporate roles will be Jamie Macdonald, Chief Operating Officer; John Potthoff, PhD, President; David Gill, Chief Financial Officer; Neil MacAllister, Executive Vice President, Corporate and Business Development, INC Research and President, AVOS Consulting; and Mark Roseman, DSc, Executive Vice President, Business Development and Marketing.
With the addition of Kendle, INC Research now employs approximately 5,000 employees across six continents with experience spanning more than 100 countries. The new organization is more strongly positioned to deliver clinical trials of all sizes across the drug development spectrum. This transaction follows INC Research’s recent acquisition of Trident Clinical Research, which is now a wholly owned affiliate operating in Sydney, Brisbane, Melbourne, Adelaide, Auckland and Mumbai.
“Biopharmaceutical companies of all sizes are relying on outsourcing partners earlier in the clinical trials process,” said Ogle. “This transaction has enhanced our value proposition to global drug developers and given us a broader range of local operations with global oversight, allowing us to maintain high standards and quality results.”
INC Research has deployed a joint integration team that already has begun fully integrating the two companies' customers, employees, and services.